IPO registrations (S-1, F-1) · Registrants
MyoKardia, Inc.
- SEC CIK
- 1552451 · filings on EDGAR ↗
- Name on the registration
- MyoKardia Inc
- Former names
- MyoKardia Inc (2012–2020)
- Registration
- Form S-1, first filed 2015-09-28, last 2016-09-26; 2 initial registrations, 5 amendments
- Outcome
- Final prospectus filed 2015-10-29; declared effective 2015-10-28
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1000 SIERRA POINT PARKWAY, Brisbane, CA 94005
- EIN
- 45-5500552
- EDGAR entity type
- operating
- Insiders and CEO pay
- MyoKardia, Inc. on the corporate pages
Offering terms
- Proposed price range
- $15.00–$17.00 per share (S-1/A filed 2015-10-23)
- Final price
- $10.00 per share, below the range (424B4 filed 2015-10-29, an initial public offering)
- Shares sold
- 5,437,500
- Gross proceeds
- $54,375,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol MYOK
- Lead underwriters
- Credit Suisse (2,310,938 shares); Cowen (1,767,187 shares)
- Syndicate
- Wells Fargo (815,625); Wedbush Securities (543,750)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: MYOKARDIA, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: MYOKARDIA INC. EXACT (EIN (EXACT))
- Form D issuer: MyoKardia Inc EXACT (CIK (EXACT))
- Lobbying client: MYOKARDIA Fuzzy (name and state)
- Lobbying client: MYOKARDIA Fuzzy (name and state)
- SEC filer: MyoKardia Inc EXACT (CIK (EXACT))
- Person page: Mark J Levin Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
Filings 14
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2015-09-28 | S-1 | S-1 (registration) | MyoKardia Inc | 0001193125-15-330059 ↗ |
| 2015-10-13 | S-1/A | S-1/A (amendment) | MyoKardia Inc | 0001193125-15-342828 ↗ |
| 2015-10-19 | S-1/A | S-1/A (amendment) | MyoKardia Inc | 0001193125-15-346145 ↗ |
| 2015-10-23 | S-1/A | S-1/A (amendment) | MyoKardia Inc | 0001193125-15-352130 ↗ |
| 2015-10-27 | S-1/A | S-1/A (amendment) | MyoKardia Inc | 0001193125-15-354454 ↗ |
| 2015-10-28 | S-1MEF | S-1MEF (added securities) | MyoKardia Inc | 0001193125-15-356568 ↗ |
| 2015-10-28 | EFFECT | EFFECT (declared effective) | MyoKardia Inc | 9999999995-15-002897 ↗ |
| 2015-10-29 | 424B4 | 424B4 (final prospectus) | MyoKardia Inc | 0001193125-15-356933 ↗ |
| 2016-09-16 | S-1 | S-1 (registration) | MyoKardia Inc | 0001193125-16-712279 ↗ |
| 2016-09-26 | S-1/A | S-1/A (amendment) | MyoKardia Inc | 0001193125-16-719919 ↗ |
| 2016-09-27 | EFFECT | EFFECT (declared effective) | MyoKardia Inc | 9999999995-16-005801 ↗ |
| 2016-09-28 | 424B4 | 424B4 (final prospectus) | MyoKardia Inc | 0001193125-16-723794 ↗ |
| 2017-01-19 | EFFECT | EFFECT (declared effective) | MyoKardia Inc | 9999999995-17-000172 ↗ |
| 2017-07-21 | EFFECT | EFFECT (declared effective) | MyoKardia Inc | 9999999995-17-001899 ↗ |
Prospectus pages read 3
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2015-10-23 | S-1/A | registration statement | $15.00–$17.00 | 4,687,500 | - | Nasdaq MYOK | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2015-10-27 | S-1/A | registration statement | - | - | 0 | primary document; no terms found | document ↗ | |||
| 2015-10-29 | 424B4 | final prospectus | $10.00 | 5,437,500 | $54,375,000 | Nasdaq MYOK | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bauer Jake | Officer | Chief Business Officer; See Remarks | 36 | 2015–2020 | |
| Chan Steven | Officer | See Remarks | 4 | 2015–2017 | |
| Fox Jonathan C | Officer | Chief Medical Officer | 3 | 2015–2016 | |
| GIANAKAKOS ANASTASIOS | Director,Officer | CEO and President; CEO, President; President and CEO | 68 | 2015–2020 | |
| HOMCY CHARLES J | Director | 3 | 2015–2016 | ||
| Lambing Joseph | Officer | See Remarks | 19 | 2015–2019 | |
| LEVIN MARK J | TenPercentOwner | 12 | 2015–2018 | person page Fuzzy | |
| McDowell Robert Scott | Officer | Chief Scientific Officer; See Remarks; Senior VP, Drug Discovery | 14 | 2015–2020 | |
| PERRY MARK L | Director | 11 | 2015–2020 | ||
| Sanofi | TenPercentOwner | 6 | 2015–2019 | ||
| STARR KEVIN P | Director,TenPercentOwner | 13 | 2015–2018 | ||
| TEPPER ROBERT I | TenPercentOwner | 11 | 2015–2018 | ||
| Third Rock Ventures GP III, L.P. | TenPercentOwner | 3 | 2015–2018 | ||
| Third Rock Ventures GP II, L.P. | TenPercentOwner | 10 | 2015–2018 | ||
| Third Rock Ventures III, L.P. | TenPercentOwner | 3 | 2015–2018 | ||
| Third Rock Ventures II, L.P. | TenPercentOwner | 10 | 2015–2018 | ||
| TOPOL ERIC | Director | 3 | 2015–2017 | ||
| TRV GP III, LLC | TenPercentOwner | 3 | 2015–2018 | ||
| TRV GP II, LLC | TenPercentOwner | 10 | 2015–2018 | ||
| AGARWAL SUNIL | Director | 10 | 2016–2020 | ||
| CRANSTON MARY B | Director | 12 | 2016–2020 | ||
| Semigran Marc | Officer | Chief Medical Officer | 9 | 2016–2019 | |
| Lee June | Officer | Chief Operating Officer; EVP, Chief Development Officer; See Remarks | 16 | 2017–2019 | |
| Popovits Kimberly J | Director | 9 | 2017–2020 | ||
| YARNO WENDY L | Director | 10 | 2017–2020 | ||
| Meeker David P | Director | 9 | 2017–2020 | ||
| LADD CYNTHIA J | Officer | General Counsel | 6 | 2018–2020 | |
| Harris Taylor C. | Officer | Chief Financial Officer | 9 | 2018–2020 | |
| Fairey William | Officer | EVP, Chief Commercial Officer; See Remarks | 5 | 2019–2020 | |
| Waynick Denelle J | Officer | Chief Legal Officer; General Counsel | 3 | 2020 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2015-04-30 | MyoKardia Inc | Biotechnology | $46,000,001 | $46,000,001 | 9 | 1 |
| 2014-08-22 | MyoKardia Inc | Biotechnology | $10,000,000 | $10,000,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | MYOKARDIA, INC. | CA | State business registries | name and state |
| Plan sponsor | MYOKARDIA INC. | FL | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | MyoKardia Inc | CA | Form D private offerings | CIK (EXACT) |
| Lobbying client | MYOKARDIA | CA | Federal lobbying (LDA) | name and state |
| Lobbying client | MYOKARDIA | CA | Federal lobbying (LDA) | name and state |
| Patent assignee | MYOKARDIA, INC. | CA | Patents (USPTO) | name and state |
| SEC filer | MyoKardia, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | MyoKardia, Inc. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | MYOKARDIA INC. | EIN (EXACT) | ||
| Person page | Mark J Levin | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CA first:
- NovaCardia Inc CA
- Bioquest Corp CA
- Regen BioPharma Inc CA
- CONNETICS CORP CA
- SIBIA NEUROSCIENCES INC CA
- MEDIVATION, INC. CA
- IMMUSOL INC CA
- DYNAVAX TECHNOLOGIES CORP CA
- RIGEL PHARMACEUTICALS INC CA
- Diadexus, Inc. CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health